Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Topical, Surgery, Photodynamic Therapy), By Drug Class, By End Use, By Region, And Segment Forecasts, 2019 - 2026

Published: Jun, 2019 | Pages: 103 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global actinic keratosis treatment market size is expected to reach over USD 9.12 billion by 2026, according to a new study by Grand View Research Inc. It is anticipated to expand at a CAGR of 4.8% during the forecast period. The market is driven high prevalence of the disease, rapid technological advancements, and rise in consumer awareness.

Topical therapeutics generated the highest revenue among other therapeutic segments, in 2018. However, photodynamic therapy is anticipated to witness a healthy growth through the forecast period. Rising trend of photodynamic and combination therapies is expected to favorably drive the growth in near future.

North America led the actinic keratosis treatment market in 2018, driven by high prevalence of disease, presence of key manufacturers, and several awareness campigns initiated by public and provate organizations. North America is anticipated to maintain its leading position throughout the forecast period. Asia Pacific, on the other hand, is anticipated to witness the fastest growth, supported by a rising disposable income and favorable government initiatives.

Some key marekt players include Bausch Health Companies Inc.; LEO Pharma A/S; Almirall, S.A.; Biofrontera, Inc.; Nestle S.A.; Sun Pharmaceutical Industries Ltd.; Novartis International AG; 3M Pharmaceuticals Inc.; Hill Dermaceuticals, Inc.; and Mylan N.V. They are developing novel kits and therapies or drugs to target population in the areas with high unmet clinical needs.

Further key findings from the study suggest:

• Topical therapeutics captured over 45% of the actinic keratosis treatment market share in 2018, driven by strong commercial sales of topical products

• Photodynamic therapy and photoenhancers are expected to witness the fastest growth over the forecast period

• Although hospitals led the end use in 2018, homecare is gaining ground swiftly

• Nearly 10% of all actinic keratosis cases advance into squamous cell cancer. The treatment of actinic keratosis as a cancer prevention strategy has fueled the treatment rates

• Strategic mergers and acquisitions among major players are one of the key growth drivers

 Table of Contents

Chapter 1 Methodology and Scope
                   1.1 Market Segmentation and Scope
                       1.1.1 Segment scope
                       1.1.2 Regional scope
                       1.1.3 Estimates and forecast timeline
                   1.2 Research Methodology
                   1.3 Information Procurement
                       1.3.1 Purchased database:
                       1.3.2 GVR's internal database
                       1.3.3 Secondary sources
                       1.3.4 Primary research
                       1.3.5 Details of primary research
                           1.3.5.1 Data for primary interviews in North america
                           1.3.5.2 Data for primary interviews in Europe
                           1.3.5.3 Data for primary interviews in Asia Pacific
                           1.3.5.4 Data for primary interviews in Middle East and Africa
                   1.4 Information or Data Analysis
                       1.4.1 Data analysis models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                       1.6.1 Commodity Flow Analysis (Model 1)
                           1.6.1.1 Approach 1: Commodity Flow Approach
                       1.6.2 Volume price analysis (Model 2)
                           1.6.2.1 Approach 2: Volume price analysis
                   1.7 List of Secondary Sources
                   1.8 List of Abbreviations
                   1.9 Objectives
                       1.9.1 Objective 1
                       1.9.2 Objective 2
                       1.9.3 Objective 3
                       1.9.4 Objective 4
Chapter 2 Executive Summary
                   2.1 Market Outlook
                   2.2 Segment Outlook
                   2.3 Competitive Insights
Chapter 3 Actinic Keratosis Treatment Market Variables, Trends & Scope
                   3.1 Disease Primer and Epidemiology
                   3.2 Market Lineage Outlook
                       3.2.1 Parent market outlook
                       3.2.2 Ancillary market outlook
                   3.3 Penetration & Growth Prospect Mapping
                   3.4 Product Pipeline Analysis, by Stage
                   3.5 User Perspective Analysis
                       3.5.1 Consumer Behavior Analysis
                   3.6 List of Key End Users
                   3.7 Regulatory Framework
                   3.8 Market Dynamics
                       3.8.1 Market driverS analysis
                           3.8.1.1 Increasing disease prevalence
                           3.8.1.2 Preventive strategies
                           3.8.1.3 Ease of availability of treatment
                       3.8.2 Market restrainTS analysis
                           3.8.2.1 Lack of consumer awareness
                           3.8.2.2 Generic penetration
                   3.9 Actinic Keratosis: Market Analysis Tools
                       3.9.1 Industry analysis - Porter's
                       3.9.2 PESTLE analysis
                       3.9.3 Major deals and strategic alliances
                           3.9.3.1 New Product Launch
                           3.9.3.2 Acquisition
                           3.9.3.3 Expansion
                           3.9.3.4 Partnerships
                           3.9.3.5 Marketing & Promotions
Chapter 4 Actinic Keratosis Treatment Market: Segment Analysis, By Therapy, 2014 - 2026 (USD Million)
                   4.1 Definition and Scope
                   4.2 Therapy Type Market Share Analysis, 2018 & 2026
                   4.3 Segment Dashboard
                   4.4 Global Actinic Keratosis Market, by Therapy, 2014 to 2026
                   4.5 Market Size & Forecasts and Trend Analyses, 2014 to 2026
                       4.5.1 Topical
                           4.5.1.1 Topical market, 2014 - 2026 (USD Million)
                       4.5.2 Surgery
                           4.5.2.1 Surgery market, 2014 - 2026 (USD Million)
                       4.5.3 Photodynamic therapy
                           4.5.3.1 Photodynamic therapy market, 2014 - 2026 (USD Million)
Chapter 5 Actinic Keratosis Treatment Market: Segment Analysis, By Drug Class, 2014 - 2026 (USD Million)
                   5.1 Definition and Scope
                   5.2 Drug Class Type Market Share Analysis, 2018 & 2026
                   5.3 Segment Dashboard
                   5.4 Global Actinic Keratosis Market, by Drug Class, 2014 to 2026
                   5.5 Market Size & Forecasts and Trend Analyses, 2014 to 2026
                       5.5.1 Nucleoside metabolic inhibitors
                           5.5.1.1 Nucleoside metabolic inhibitors market, 2014 - 2026 (USD Million)
                       5.5.2 Nonsteroidal antiinflammatory drugs
                           5.5.2.1 NSAIDs market, 2014 - 2026 (USD Million)
                       5.5.3 Immune response modifiers
                           5.5.3.1 Immune response modifiers market, 2014 - 2026 (USD Million)
                       5.5.4 Photoenhancers
                           5.5.4.1 Photoenhancers market, 2014 - 2026 (USD Million)
                       5.5.5 Others
                           5.5.5.1 Others market, 2014 - 2026 (USD Million)
Chapter 6 Actinic Keratosis Treatment Market: Segment Analysis, By End use, 2014 - 2026 (USD Million)
                   6.1 Definition and Scope
                   6.2 End use Type Market Share Analysis, 2018 & 2026
                   6.3 Segment Dashboard
                   6.4 Global Actinic Keratosis Market, by End use, 2014 to 2026
                   6.5 Market Size & Forecasts and Trend Analyses, 2014 to 2026
                       6.5.1 Hospitals
                           6.5.1.1 Hospitals market, 2014 - 2026 (USD Million)
                       6.5.2 Private clinics
                           6.5.2.1 Private clinics market, 2014 - 2026 (USD Million)
                       6.5.3 Homecare
                           6.5.3.1 Homecare market, 2014 - 2026 (USD Million)
                       6.5.4 Others
                           6.5.4.1 Others market, 2014 - 2026 (USD Million)
Chapter 7 Actinic Keratosis Treatment Market: Regional Market Analysis, 2014 - 2026 (USD Million)
                   7.1 Definition & Scope
                   7.2 Regional Market Share Analysis, 2018 & 2026
                   7.3 Regional Market Dashboard
                   7.4 Regional Market Snapshot
                   7.5 Regional Market Share and Leading Players, 2018
                       7.5.1 North america
                       7.5.2 Europe
                       7.5.3 Asia Pacific
                       7.5.4 Latin America
                       7.5.5 Middle East and Africa
                   7.6 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
                       7.6.1 North America
                       7.6.2 Europe
                       7.6.3 Asia Pacific
                       7.6.4 Latin America
                       7.6.5 Middle East and Africa
                   7.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2018 to 2026
                       7.7.1 North America
                           7.7.1.1 North America market estimates and forecast, 2014-2026 (USD Million)
                           7.7.1.2 U.S.
                               7.7.1.2.1 U.S. actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.1.3 Canada
                               7.7.1.3.1 Canada actinic keratosis treatment market, 2014 - 2026 (USD Million)
                       7.7.2 Europe
                           7.7.2.1 Europe actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.2.2 U.K.
                               7.7.2.2.1 U.K. actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.2.3 Germany
                               7.7.2.3.1 Germany actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.2.4 Spain
                               7.7.2.4.1 Spain actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.2.5 France
                               7.7.2.5.1 France actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.2.6 Italy
                               7.7.2.6.1 Italy actinic keratosis treatment market, 2014 - 2026 (USD Million)
                       7.7.3 Asia Pacific
                           7.7.3.1 Asia Pacific actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.3.2 Japan
                               7.7.3.2.1 Japan actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.3.3 China
                               7.7.3.3.1 China actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.3.4 India
                               7.7.3.4.1 India actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.3.5 South Korea
                               7.7.3.5.1 South Korea actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.3.6 Australia
                               7.7.3.6.1 Australia actinic keratosis treatment market, 2014 - 2026 (USD Million)
                       7.7.4 Latin America
                       7.7.5 Latin America actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.5.1 Brazil
                               7.7.5.1.1 Brazil actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.5.2 Mexico
                               7.7.5.2.1 Mexico actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.5.3 Argentina
                               7.7.5.3.1 Argentina actinic keratosis treatment market, 2014 - 2026 (USD Million)
                       7.7.6 MEA
                           7.7.6.1 MEA actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.6.2 South Africa
                               7.7.6.2.1 South Africa actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.6.3 Saudi Arabia
                               7.7.6.3.1 Saudi Arabia actinic keratosis treatment market, 2014 - 2026 (USD Million)
                           7.7.6.4 UAE
                               7.7.6.4.1 UAE actinic keratosis treatment market, 2014 - 2026 (USD Million)
Chapter 8 Actinic keratosis treatment market - Competitive Analysis
                   8.1 Recent Developments & Impact Analysis, by Key Market Participants
                       8.1.1 Ansoff matrix
                       8.1.2 Heat map analysis
                   8.2 Company Categorization
                       8.2.1 Innovators
                       8.2.2 Market Leaders
                   8.3 Vendor Landscape
                       8.3.1 List of key distributors and channel partners
                       8.3.2 Key customers
                       8.3.3 Key company market share analysis, 2018
                   8.4 Public Companies
                       8.4.1 Company market position analysis
                       8.4.2 Company Market Share, by region
                       8.4.3 Competitive Dashboard Analysis
                       8.4.3.1 Market Differentiators
                   8.5 Private Companies
                       8.5.1 List of key emerging companies
                       8.5.3 Regional network map
                       8.5.4 Company market position analysis
                   8.6 Supplier Ranking
                   8.7 Company Profiles
                       8.7.1 Bausch Health Companies Inc.
                           8.7.1.1 Company overview
                           8.7.1.2 Financial performance
                           8.7.1.3 Product benchmarking
                           8.7.1.4 Strategic initiatives
                       8.7.2 LEO Pharma A/S
                           8.7.2.1 Company overview
                           8.7.2.2 Financial performance
                           8.7.2.3 Product benchmarking
                           8.7.2.4 Strategic initiatives
                       8.7.3 Almirall, S.A.
                           8.7.3.1 Company overview
                           8.7.3.2 Financial performance
                           8.7.3.3 Product benchmarking
                           8.7.3.4 Strategic initiatives
                       8.7.4 Biofrontera AG
                           8.7.4.1 Company overview
                           8.7.4.2 Financial performance
                           8.7.4.3 Product benchmarking
                           8.7.4.4 Strategic initiatives
                       8.7.5 Nestlé S.A.
                           8.7.5.1 Company overview
                           8.7.5.2 Financial performance
                           8.7.5.3 Product benchmarking
                           8.7.5.4 Strategic initiatives
                       8.7.6 Sun Pharmaceutical Industries Ltd.
                           8.7.6.1 Company overview
                           8.7.6.2 Financial performance
                           8.7.6.3 Product benchmarking
                           8.7.6.4 Strategic initiatives
                       8.7.7 Novartis AG
                           8.7.7.1 Company overview
                           8.7.7.2 Financial performance
                           8.7.7.3 Product benchmarking
                           8.7.7.4 Strategic initiatives
                       8.7.8 Hill Dermaceuticals, Inc.
                           8.7.8.1 Company overview
                           8.7.8.2 Product benchmarking
                           8.7.8.3 Strategic initiatives
                       8.7.9 3M Pharmaceuticals Inc.
                           8.7.9.1 Company overview
                           8.7.9.2 Financial performance
                           8.7.9.3 Product benchmarking
                           8.7.9.4 Strategic initiatives
                       8.7.10 Mylan N.V.
                           8.7.10.1 Company overview
                           8.7.10.2 Financial performance
                           8.7.10.3 Product benchmarking
                           8.7.10.4 Strategic initiatives
Chapter 9 Recommendations

List of Tables

Table 1 Primary interview details: North America
Table 2 Primary interview details: Europe
Table 3 Primary interview details: Asia Pacific
Table 4 Primary interview details: Middle East and Africa
Table 5 List of secondary sources
Table 6 List of abbreviations
Table 7 Actinic Keratosis Epidemiology - 2018 (%)
Table 8 Product pipeline
Table 9 Regulatory framework
Table 10 Key topical products for actinic keratosis, 2018
Table 11 Key surgical procedures for actinic keratosis, 2018
Table 12 Key photodynamic therapeutics for actinic keratosis, 2018
Table 13 Key NMIs for actinic keratosis, 2018
Table 14 Key NSAIDs for actinic keratosis, 2018
Table 15 Key IRMs for actinic keratosis, 2018
Table 16 Key photoenhancers for actinic keratosis, 2018
Table 17 Other drug classes for actinic keratosis, 2018
Table 18 North America actinic keratosis treatment, by country, 2014 - 2026 (USD Million)
Table 19 North America actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 20 North America actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 21 North America actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 22 U.S. actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 23 U.S. actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 24 U.S. actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 25 Canada actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 26 Canada actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 27 Canada actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 28 Europe actinic keratosis treatment, by country, 2014 - 2026 (USD Million)
Table 29 Europe actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 30 Europe actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 31 Europe actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 32 U.K. actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 33 U.K. actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 34 U.K. actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 35 Germany actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 36 Germany actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 37 Germany actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 38 Spain actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 39 Spain actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 40 Spain actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 41 France actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 42 France actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 43 France actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 44 Italy actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 45 Italy actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 46 Italy actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 47 Asia Pacific actinic keratosis treatment, by country, 2014 - 2026 (USD Million)
Table 48 Asia Pacific actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 49 Asia Pacific actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 50 Asia Pacific actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 51 Japan actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 52 Japan actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 53 Japan actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 54 China actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 55 China actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 56 China actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 57 India actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 58 India actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 59 India actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 60 South Korea actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 61 South Korea actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 62 South Korea actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 63 Australia actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 64 Australia actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 65 Australia actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 66 Latin America actinic keratosis treatment, by country, 2014 - 2026 (USD Million)
Table 67 Latin America actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 68 Latin America actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 69 Latin America actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 70 Brazil actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 71 Brazil actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 72 Brazil actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 73 Mexico actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 74 Mexico actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 75 Mexico actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 76 Argentina actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 77 Argentina actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 78 Argentina actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 79 MEA actinic keratosis treatment, by country, 2014 - 2026 (USD Million)
Table 80 MEA actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 81 MEA actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 82 MEA actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 83 South Africa actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 84 South Africa actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 85 South Africa actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 86 Saudi Arabia actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 87 Saudi Arabia actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 88 Saudi Arabia actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 89 UAE actinic keratosis treatment, by therapy, 2014 - 2026 (USD Million)
Table 90 UAE actinic keratosis treatment, by drug class, 2014 - 2026 (USD Million)
Table 91 UAE actinic keratosis treatment, by end use, 2014 - 2026 (USD Million)
Table 92 Leading market players anticipated to witness highest growth

List of Figures

Fig. 1 Actinic keratosis treatment market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Primary interviews in North America
Fig. 6 Primary interviews in Europe
Fig. 7 Primary interviews in Asia Pacific
Fig. 8 Primary interviews in Middle East and Africa
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Market outlook (2018)
Fig. 14 Segment Outlook (Therapy, 2018)
Fig. 15 Strategy framework
Fig. 16 Actinic keratosis epidemiology- 2018
Fig. 17 Penetration & growth prospect mapping
Fig. 18 Consumer behavior analysis
Fig. 19 Market driver relevance analysis (Current & future impact)
Fig. 20 Market restraint relevance analysis (Current & future impact)
Fig. 21 Porter's five forces analysis
Fig. 22 PESTLE analysis
Fig. 23 Strategy mapping
Fig. 24 Actinic keratosis treatment market: Therapy movement analysis
Fig. 25 Therapy segment dashboard
Fig. 26 Actinic keratosis market therapy outlook: Key takeaways
Fig. 27 Topical market, 2014 - 2026 (USD Million)
Fig. 28 Surgery market, 2014 - 2026 (USD Million)
Fig. 29 Photodynamic therapy market, 2014 - 2026 (USD Million)
Fig. 30 Actinic keratosis treatment market: Drug class movement analysis
Fig. 31 Drug class segment dashboard
Fig. 32 Actinic keratosis market drug class outlook: Key takeaways
Fig. 33 Nucleoside metabolic inhibitors market, 2014 - 2026 (USD Million)
Fig. 34 NSAIDs market, 2014 - 2026 (USD Million)
Fig. 35 Immune response modifiers market, 2014 - 2026 (USD Million)
Fig. 36 Photoenhancers market, 2014 - 2026 (USD Million)
Fig. 37 Other drug classes market, 2014 - 2026 (USD Million)
Fig. 38 Actinic keratosis treatment market: End use movement analysis
Fig. 39 End use segment dashboard
Fig. 40 Actinic keratosis market end use outlook: Key takeaways
Fig. 41 Hospitals market, 2014 - 2026 (USD Million)
Fig. 42 Private clinics market, 2014 - 2026 (USD Million)
Fig. 43 Homecare market, 2014 - 2026 (USD Million)
Fig. 44 Other end use market, 2014 - 2026 (USD Million)
Fig. 45 Regional outlook, 2018 & 2026
Fig. 46 Regional market dashboard
Fig. 47 Regional market place: Key takeaways
Fig. 48 North America market share and leading players (2018)
Fig. 49 Europe market share and leading players (2018)
Fig. 50 Asia Pacific market share and leading players (2018)
Fig. 51 Latin America market share and leading players (2018)
Fig. 52 Middle East and Africa market share and leading players (2018)
Fig. 53 North America, SWOT, by PESTEL
Fig. 54 Europe, SWOT, by PESTEL
Fig. 55 Asia Pacific,, SWOT, by PESTEL
Fig. 56 Latin America, SWOT, by PESTEL
Fig. 57 Middle East and Africa, SWOT, by PESTEL
Fig. 58 North America
Fig. 59 North America actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 60 U.S.
Fig. 61 U.S. actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 62 Canada
Fig. 63 Canada actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 64 Europe
Fig. 65 Europe actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 66 U.K..
Fig. 67 U.K.. actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 68 Germany
Fig. 69 Germany actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 70 Spain
Fig. 71 Spain actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 72 France
Fig. 73 France actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 74 Italy
Fig. 75 Italy actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 76 Asia Pacific
Fig. 77 Asia Pacific actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 78 Japan
Fig. 79 Japan actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 80 China
Fig. 81 China actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 82 India
Fig. 83 India actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 84 South Korea
Fig. 85 South Korea actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 86 Australia
Fig. 87 Australia actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 88 Latin America
Fig. 89 Latin America actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 90 Brazil
Fig. 91 Brazil actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 92 Mexico
Fig. 93 Mexico actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 94 Argentina
Fig. 95 Argentina actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 96 Middle East and Africa
Fig. 97 MEA actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 98 South Africa
Fig. 99 South Africa actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 100 Saudi Arabia
Fig. 101 Saudi Arabia actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 102 UAE
Fig. 103 UAE actinic keratosis treatment market, 2014 - 2026 (USD Million)
Fig. 104 Ansoff Matrix
Fig. 105 Heat map analysis
Fig. 106 Market penetration vs growth prospect mapping
Fig. 107 Company market share analysis
Fig. 108 Company market position analysis
Fig. 109 Company market share, by region
Fig. 110 Market differentiators
Fig. 111 Regional network map